Noman Rafique, MD
Hematology & Oncology · Massillon, OHNPI 1043215676
Payments from drug & device makers
Across 889 payments — averaging $559.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$159K
- E.r. Squibb & Sons, L.L.C.$140K
- Astrazeneca UK Limited$51K
- Mirati Therapeutics, Inc.$48K
- Regeneron$34K
- AstraZeneca$29K
- plus $35K from 54 others
What the payments were for
- Consulting fees$1,95811%
- Speaking & faculty fees$1501%
- Food & beverage$14,67885%
- Education$5513%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$497,219 in reported general payments places this provider in the 80th percentile of 450 hematology & oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 118 | $1,620,022 |
| PomalystPomalidomide | 54 | $1,176,891 |
| RevlimidLenalidomide | 57 | $1,014,450 |
| Lenalidomide | 67 | $897,933 |
| KisqaliRibociclib Succinate | 54 | $841,487 |
| ImbruvicaIbrutinib | 48 | $768,477 |
| NubeqaDarolutamide | 50 | $659,144 |
| PromactaEltrombopag Olamine | 18 | $586,360 |
| LenvimaLenvatinib Mesylate | 24 | $583,565 |
| Somatuline DepotLanreotide Acetate | 69 | $574,820 |
| ErleadaApalutamide | 34 | $486,773 |
| VenclextaVenetoclax | 44 | $467,065 |
| OrserduElacestrant Hcl | 20 | $465,559 |
| TagrissoOsimertinib Mesylate | 27 | $442,852 |
| CabometyxCabozantinib S-Malate | 17 | $413,837 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisKisqali, Promacta, Tasigna, Gleevec | $1,076 | $1,977,138112 claims |
| Astellas Pharma US IncXtandi | $454 | $1,620,022118 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $139,599 | $1,176,89154 claims |
| Bristol Myers SquibbRevlimid | $1,056 | $1,014,45057 claims |
| PfizerInlyta, Octagam, Eliquis, Ibrance | $14,606 | $966,954351 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $265 | $768,47748 claims |
| Johnson & JohnsonErleada, Procrit, Xarelto | $1,865 | $711,610197 claims |
| BayerNubeqa | $127 | $659,14450 claims |
| Eisai Inc.Lenvima | $703 | $583,56524 claims |
| Ipsen Biopharmaceuticals, IncSomatuline Depot | $155 | $574,82069 claims |
| AbbVieVenclexta | $305 | $467,06544 claims |
| Stemline Therapeutics Inc.Orserdu | $145 | $465,55920 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 450 hematology & oncology providers in Ohio.
Other hematology & oncology in Massillon
- Nagaprasad NagajothiMassillon$762K
- Afshin DowlatiCleveland$25.1M
- Brian HillCleveland$11.6M
- Trisha Wise-DraperCincinnati$9.8M
- Davendra SohalCincinnati$8.6M
- Christopher HoimesCleveland$7.5M
- Balazs HalmosCleveland$7M
- David WaterhouseCincinnati$5.7M
- Dale ShepardCleveland$5.1M
- Paolo CaimiCleveland$4.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.